Tag: SARS-CoV-2

  • Congressman off-base in ad claiming Fauci shipped covid to Montana before the pandemic

    Congressman off-base in ad claiming Fauci shipped covid to Montana before the pandemic

    [ad_1]

    A fundraising ad for U.S. Rep. Matt Rosendale (R-Mont.) shows a photo of Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases, behind bars, swarmed by flying bats.

    Rosendale, who is eyeing a challenge to incumbent Sen. Jon Tester, a Democrat, maintains that a Montana biomedical research facility, Rocky Mountain Laboratories in Hamilton, has a dangerous link to the pandemic. This claim is echoed in the ad:

    “It’s been revealed that Fauci brought COVID to the Montana one year before COVID broke out in the U.S!,” it charges in all-caps before asking readers to “Donate today and hold the D.C. bureaucracy accountable!”

    The ad, paid for by Matt Rosendale for Montana, seeks contributions through WinRed, a platform that processes donations for Republican candidates. Rosendale also shared the fundraising pitch on his X account Nov. 1, and it remained live as of early February.

    Rosendale made similar accusations on social media, during a November speech on the U.S. House floor, and through his congressional office. Sometimes his comments, like those on the House floor, are milder, saying the researchers experimented on “a coronavirus” leading up to the pandemic. Other times, as in an interview with One America News Network, he linked the lab’s work to covid-19’s spread.

    In that interview clip, Rosendale recounted pandemic-era shutdowns before saying, “And now we’re finding out that the National Institute of Health, Rocky Mountain Lab, down in Hamilton, Montana, had also played a role in this.”

    Rosendale’s statements echo broader efforts to scrutinize how research into viruses happens in the United States and is part of a continued wave of backlash against scientists who have studied coronaviruses. Rosendale is considering seeking the Republican nomination to challenge Tester, in a toss-up race that could help determine which party controls the Senate in 2025. Political newcomer Tim Sheehy is also seeking the Republican nomination for the Senate.

    Rosendale proposed amendments to a health spending bill that would ban pandemic-related pathogen research funding for Rocky Mountain Laboratories and cut the salary of one of its top researchers, virologist Vincent Munster, to $1. The House has included both amendments in the Health and Human Services budget bill that the Republican majority hopes to pass. A temporary spending bill is funding the health department until March.

    We contacted Rosendale’s congressional office multiple times — with emails, a phone call, and an online request — asking what proof he had to back up his statements that the Montana lab infected bats with covid from China before the outbreak. We got no reply.

    Kathy Donbeck, of the National Institute of Allergy and Infectious Diseases’ Office of Communications and Government Relations, said in an email that the ad’s claims are false. Interviews with virologists and a review of the research paper published shortly before Rosendale’s assertions support that position.

    Where this is coming from

    Rosendale’s statements seem to stem from a Rocky Mountain Laboratories study from 2016 that looked into how a coronavirus, WIV1-CoV, acted in Egyptian fruit bats. The work, published by the journal Viruses in 2018, showed that the specific strain didn’t cause a robust infection in the bats.

    The study did not receive widespread attention at the time. But on Oct. 30, 2023, the study was highlighted by a blog called White Coat Waste Project, which says its mission is to stop taxpayer-funded experiments on animals. Some right-wing media outlets began to connect the Montana lab with the coronavirus that causes covid.

    Rosendale’s office issued an Oct. 31 news release saying the Wuhan Institute of Virology in China “shipped a strain of coronavirus” to the Hamilton lab. “Our government helped create the Wuhan flu, then shut the country down when it escaped from the lab,” Rosendale said.

    It’s a different virus

    Rocky Mountain Laboratories is a federally funded facility as part of NIAID, the nation’s top infectious disease research agency, which Fauci led for nearly 40 years.

    According to the study and Donbeck’s email, the Montana researchers focused on a coronavirus called WIV1-CoV, not the covid-causing SARS-CoV-2. They’re different viruses.

    “The genetics of the viruses are very different, and their behavior biologically is very different,” said Troy Sutton, a virologist with Pennsylvania State University who has studied the evolution of pandemic influenza viruses.

    In a review of media reports on the Montana study, Health Feedback, a network of scientists that fact-checks health and medical media coverage, showed the virus’s lineage indicated that WIV1 “is not a direct ancestor or even a close relative of SARS-CoV-2.”

    Additionally, the description of the coronavirus strain as being “shipped” suggests that it physically traveled across the world. That’s not what happened.

    The Wuhan Institute of Virology provided the WIV1 virus’s sequence that allowed researchers to make a lab-grown copy. A separate study, published in 2013 by the journal Nature, outlines the origins of the lab-created virus.

    According to the study’s methodology, the researchers used a clone of WIV1. An NIAID statement to Lee Enterprises, a media company, said the virus “was generated using common laboratory techniques, based on genetic information that was publicly shared by Chinese scientists.”

    Stanley Perlman, a University of Iowa professor who studies coronaviruses and serves on the federal advisory committee that reviews vaccines, said Rosendale’s claim is off-base.

    He said Rosendale’s focus on where the lab got its materials is irrelevant and serves “only to make people wary and scared.”

    Rosendale’s efforts to prohibit particular research at Rocky Mountain Laboratories appear ill-informed, too. Rosendale targeted banning gain-of-function research, which involves altering a pathogen to study its spread. In her email, NIAID’s Donbeck said the Rocky Mountain Laboratories study didn’t involve gain-of-function research.

    This type of research has long been controversial, and people who study viruses have said the definition of “gain of function” is problematic and insufficient to show when research, or even work to create vaccines, could cross into that type of research.

    But both Sutton and Perlman said that, any way you look at it, the Rocky Mountain Laboratories study published in 2018 didn’t change the virus. It put a virus in bats and showed it didn’t grow.

    And it had no effect on the covid outbreak a year later, first detected in Washington state.

    Our ruling

    Rosendale’s ad said, “It’s been revealed that Fauci brought COVID to the Montana one year before COVID broke out in the U.S!” The campaign ad and Rosendale’s similar statements refer to research at the Rocky Mountain Laboratories involving WIV1, a coronavirus that researchers say is not even distantly close in genetic structure to SARS-CoV-2, the virus that caused covid-19.

    Rosendale’s claim is wrong about when the scientists began their work, what they were studying, and where they got the materials. The researchers began their work in 2016 and, although they were studying a coronavirus, it wasn’t the virus that causes covid. The Montana scientists used a lab-grown clone of WIV1 for their research. The first laboratory-confirmed case of covid was not detected in the U.S. until Jan. 20, 2020. Rosendale’s ad is inaccurate and ridiculous. We rate it Pants on Fire!

    Sources:

    Viruses, “SARS-Like Coronavirus WIV1-CoV Does Not Replicate in Egyptian Fruit Bats (Rousettus aegyptiacus),” Dec. 19, 2018

    White Coat Waste Project, “Horror Show: Shady Zoo Sent Bats to NIH to Be Infected With a Wuhan Lab Coronavirus,” Oct. 30, 2023

    MattForMontana X post, Nov. 1, 2023

    Campaign ad, accessed Dec. 14, 2023

    Rep. Matt Rosendale, House floor speech, Nov. 14, 2023

    One America News Network, interview, accessed Dec. 14, 2023

    Rosendale congressional office, “Rep. Rosendale Reacts to Reports That Wuhan Lab Shipped Coronavirus to Fauci-Run Lab in Hamilton Prior to Pandemic,” Oct. 31, 2023

    National Institute of Allergy and Infectious Diseases, “History of Rocky Mountain Labs (RML),” accessed Dec. 14, 2023

    Email exchange with NIAID, beginning Dec. 14, 2023

    Statement from NIAID provided to Lee Enterprises, accessed Jan. 2, 2024

    Nature, “Isolation and Characterization of a Bat SARS-Like Coronavirus That Uses the ACE2 Receptor,” Oct. 30, 2013

    Ravalli Republic, “Rosendale Moves to Strip Rocky Mountain Lab Research Funding,” Nov. 17, 2023

    Interview, Troy Sutton, assistant professor of veterinary and biomedical sciences at Pennsylvania State University, Jan. 5, 2024

    Interview, Stanley Perlman, professor of microbiology and immunology and professor of pediatrics at the University of Iowa, Jan. 13, 2024

    FDA, “Roster of the Vaccines and Related Biological Products Advisory Committee,” accessed Jan. 16, 2024

    Health Feedback, “2018 Coronavirus Research in NIAID Montana Lab Is Unrelated to the COVID-19 Pandemic, Contrary to Claim by Fox News’s Jesse Watters,” last accessed Jan. 17, 2024

    Email exchange with OpenSecrets, an independent research group tracking money in politics, beginning Jan. 30, 2024

    CDC Museum COVID-19 Timeline, accessed Feb. 2, 2024




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.



    [ad_2]

    Source link

  • COVID-19 recovery disparities uncovered among racial and ethnic groups

    COVID-19 recovery disparities uncovered among racial and ethnic groups

    [ad_1]

    In a recent study published in Frontiers in Public Health, researchers from the United States of America (US) investigated the racial and ethnic variation in symptoms, activity level, health status, and missed work.

    Depiction of the SARS-CoV-2 virus
    Study: Ethnic and racial differences in self-reported symptoms, health status, activity level, and missed work at 3 and 6 months following SARS-CoV-2 infection. Image Credit: Kateryna Kon/Shutterstock.com

    They assessed this via follow-ups post-initial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the symptoms were equally prevalent among the groups, they found that three and six months post-infection, Hispanic participants reported poorer health and reduced activity compared to non-Hispanic participants.

    Further, racial minority participants reported more negative impacts on health status, activity, and absence from work as compared to the White population.

    Background

    The coronavirus disease 2019 (COVID-19) pandemic highlighted disparities, wherein ethnic and racial minoritized populations were observed to face greater infection risks due to the essential nature of their work, limited remote work options, and challenges in practicing social distancing.

    The infected individuals faced barriers to care, including underinsurance and lack of primary care, with economic consequences. Disparities persisted in health outcomes, for example, higher hospitalization and mortality rates among Black and Hispanic populations.

    Despite these challenges, recovery-related differences after SARS-CoV-2 infection remained understudied, with existing studies having limitations like varied follow-up durations, inconsistent findings, and insufficient consideration of social health determinants.

    Researchers in the present study aimed to address this gap. The study assessed symptoms and health-related effects following SARS-CoV-2 infection across ethnicities and races, aiming to guide equitable health interventions effectively.

    About the study

    In the present study, a secondary analysis was performed using data from a US-based, prospective, multicenter, longitudinal cohort study named Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE). The primary cohort involved adults positive for SARS-CoV-2 infection enrolled from December 2020 to July 2022, along with a SARS-CoV-2-negative group for considering non-SARS-CoV-2-related effects.

    A total of 3,161 participants completed enrollment and reported symptoms and other outcomes every three months via surveys. Out of these participants, 2,402 were SARS-CoV-2-positive and 759 SARS-CoV-2-negative.

    Among the SARS-CoV-2-positive participants, 14.0% were Hispanic, 11.0% were Asian, 7.9% were Black, 9.9% were categorized as Other/Multiple races, and 71.1% were White. Among the SARS-CoV-2-negative participants, 16.5% were Hispanic, 14.8% were Asian, 13.1% were Black, 8.1% were categorized as Other/Multiple races, and 64% were White.

    The researchers evaluated 21 COVID-19-like symptoms and “other symptoms” at enrollment and three and six months post-infection using the Centers for Disease Control and Prevention’s symptom list.

    During the follow-ups, health status (rated on a 5-point scale from excellent to poor), activity level compared to pre-SARS-CoV-2 symptoms (same, somewhat less, much less), and missed work in the past three months (categorized into workdays) were assessed.

    Data were collected on ethnicity and race. Interactions between ethnicity or race and SARS-CoV-2 infection status were considered.

    Generalized estimating equations (GEE) logistic regression was used to estimate marginal odds ratios (ORs) for various outcomes, adjusting for SARS-CoV-2 infection status, demographic factors, substance use, social determinants of health, pre-existing health conditions, COVID-19 vaccination status, and survey time point.

    Results and discussion

    Post SARS-CoV-2 infection, symptoms were found to be mostly similar across ethnic and racial groups over time. At three months, Hispanic individuals had higher odds of reporting fair/poor health (OR = 1.94) and reduced activity compared to their non-Hispanic counterparts. No significant differences by ethnicity were observed at six months.

    At three months, participants of Other/Multiple races had higher odds of reporting fair/poor health (OR = 1.9) and reduced activity compared to White participants. At six months, Asian participants had a greater probability of reporting fair/poor health (OR = 1.88), Black individuals reported more missed work (OR = 2.83), and Other/Multiple race participants reported more health issues (OR = 1.83), reduced activity, and missed work (OR = 2.25).

    The findings help to improve our understanding of the ethnic and racial disparities in outcomes after SARS-CoV-2 infection and could be used to inform clinical and public health initiatives and policy.

    However, the study is limited by small sample sizes in ethnic and racial subgroups, lack of adjustment for insurance and frontline worker status, potential participant representativeness issues, variations in response rates, lack of exploration of neurological and mental health sequelae, recruitment at different pandemic stages, and the absence of adjustments for multiple comparisons.

    Conclusion

    In conclusion, the findings suggest that while the symptom prevalence was similar among the groups, the ethnic and racial minority groups suffered adverse effects on health status, activity level, and absence from work as compared to non-Hispanic and White populations, respectively.

    Examining the underlying factors contributing to these differences could aid the efforts to promote health equity and improve our preparedness for future pandemics.

    Journal reference:

    • O’Laughlin KN, Klabbers RE, Mannan IE, et al. (2024). Ethnic and racial differences in self-reported symptoms, health status, activity level, and missed work at 3 and 6 months following SARS-CoV-2 infection. Frontiers in Public Health. doi: 10.3389/fpubh.2023.1324636.  https://www.frontiersin.org/articles/10.3389/fpubh.2023.1324636/full

    [ad_2]

    Source link

  • XBB.1.5 updated COVID vaccine booster offers 54% increased protection against symptomatic infection

    XBB.1.5 updated COVID vaccine booster offers 54% increased protection against symptomatic infection

    [ad_1]

    In a recent study published in Morbidity and Mortality Weekly Report, researchers estimated the effectiveness of the 2023-24 updated coronavirus disease 2019 (COVID-19) vaccine.

    The Advisory Committee on the Immunization Practices of the United States (US) Centers for Disease Control and Prevention (CDC) recommended on September 12, 2023, that all individuals aged six months or older receive the 2023-24 updated monovalent COVID-19 vaccine. The updated vaccine contains a component from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5 lineage and lacks ancestral strain components.

    The JN.1 lineage was identified in the US in September 2023, which harbors 30 additional mutations in the spike (S) protein compared to XBB.1.5. Real-time reverse-transcription polymerase chain reaction (RT-PCR) results can help distinguish some SARS-CoV-2 lineages. S-gene target failure (SGTF) is detected in JN.1 and other BA.2.86 lineages, whereas S-gene target presence (SGTP) is detected in most lineages from 2023, including XBB.

    Study: Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. Image Credit: New Africa / ShutterstockStudy: Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. Image Credit: New Africa / Shutterstock

    About the study

    In the present study, researchers estimated the effectiveness of the 2023-24 updated COVID-19 vaccine against symptomatic infection. They included tests conducted between September 21, 2023, and January 14, 2024, among adults reporting at least one symptom. Cases were individuals with a positive nucleic acid amplification test (NAAT).

    Controls were individuals with a negative NAAT. The team excluded tests from Janssen vaccine recipients, Novavax recipients, immunocompromised individuals, those who received the most recent vaccine dose within a week preceding testing, and those with a positive COVID-19 test within the past 90 days.

    Vaccine effectiveness (VE) against symptomatic COVID-19 was estimated by comparing the odds of receipt of the updated vaccine versus non-receipt among cases and controls. Multivariable logistic regression was used to estimate odds ratios. VE was computed separately by SGTP and SGTF status. Test-positive samples with reduced or null S-gene amplification were deemed to have an SGTF, whereas those without SGTF were considered SGTP.

    Findings

    Of over 9,200 NAAT results for individuals with symptoms of COVID-19-like illness, 3,295 tested SARS-CoV-2-positive. Around 1,125 individuals received the updated COVID-19 vaccine ≥ seven days earlier. More controls received the updated vaccine than cases. The median time from the last dose among updated vaccine recipients was 60 days for cases and 51 days for controls.

    Nearly 8,100 individuals did not receive the updated vaccine. Of these, 30% were non-vaccinated and 70% were vaccinated. Among the vaccinated, the median time since vaccination was 378 days for cases and 363 days for controls. The estimated VE was 57% in the 18–49 age group and 46% among those aged ≥ 50. VE was estimated at 58% and 49% among people tested 7–59 and 60–119 days after receiving the updated vaccine, respectively.

    There were 679 tests available with S-gene target results. Of these, 258 showed SGTF, and 421 exhibited SGTP. VE was not precise for tests with SGTF during the 7–59 days post-receipt of the updated vaccine, given the emergence of JN.1 in the US. VE during the 60–119 days post-receipt of the updated vaccine was 60% for tests with SGTP and 49% for those with SGTF.

    Conclusions

    The study provided early efficacy estimates of the updated monovalent XBB.1.5 vaccine against symptomatic infection and the first VE estimates against the JN.1 lineage. These VE estimates include data up to 119 days post-vaccination. However, VE will likely wane with time since vaccination, as observed after the original monovalent or bivalent COVID-19 vaccination. Prior infection history, medical conditions, and vaccination status were self-reported, thereby subject to recall bias.

    Besides, the VE estimates were computed for a population that opted to be tested for COVID-19; therefore, the estimates are subject to selection biases. Further, coverage of the updated vaccine is low among adults and varies by age. Taken together, the updated monovalent vaccine provided 54% protection from symptomatic illness. Waning of the VE is expected over time, especially against less severe outcomes.

    Journal reference:

    • Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024. MMWR Morb Mortal Wkly Rep, 2024, DOI: 10.15585/mmwr.mm7304a2, https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm

    [ad_2]

    Source link